Independent register of U.S. FDA drug recalls · updated Oct 11, 2026
RxRecalls Get alerts

FDA Drug Recalls

14,806 recalls, newest first

Risk Class IClass IIClass III
Status OngoingCompletedTerminated
Year 20262025202420232022 All years
Cause Sterility / contaminationNitrosamine impurityChemical / undeclaredParticulate / foreign matterLabeling / mix-upcGMP deviationMicrobial contamination All causes
Class II · Moderate risk

Alcohol Swabsticks

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 67777-300-01 D-1327-2022
Class II · Moderate risk

Sterile Alcohol Prep Pads

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 67777-121-16 D-1326-2022
Class II · Moderate risk

Racepinephrine Inhalation Solution

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 0487-5901-99 D-1325-2022
Class II · Moderate risk

Dakin's Solution

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 0436-0672-16 D-1323-2022
Class II · Moderate risk

A&D Original Ointment

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 11523-0096-3 D-1322-2022
Class II · Moderate risk

Pataday

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 0065-8150-01 D-1321-2022
Class II · Moderate risk

GenTeal Tears

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 0065-0518-01 D-1320-2022
Class II · Moderate risk

Miralax (Polyethylene Glycol 3350)

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 11523-7234-4 D-1319-2022
Class II · Moderate risk

Debrox

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 63029-321-01 D-1318-2022
Class II · Moderate risk

Systane Zaditor

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 0065-4011-05 D-1317-2022
Class II · Moderate risk

Systane Balance

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 0065-1433-02 D-1316-2022
Class II · Moderate risk

Eye-stream

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 0065-0530-04 D-1315-2022
Class II · Moderate risk

Systane

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 0065-0429-15 D-1314-2022
Class II · Moderate risk

Naphcon A eye drops

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 0065-0085-15 D-1313-2022
Class II · Moderate risk

Bisacodyl Suppositories

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 57896-443-01 D-1312-2022
Class II · Moderate risk

Triple Antibiotic Ointment

CGMP Deviations: products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 0498-0750-36 D-1311-2022
Class II · Moderate risk

Telmisartan and Hydrochlorothiazide Tablets USP

Defective Container: Recall of these batches has been initiated due to complaints of difficult to open blister and tablet breaks while opening the blister .

Terminated Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-841-13 D-1306-2022
Class II · Moderate risk

Telmisartan and Hydrochlorothiazide Tablets USP

Defective Container: Recall of these batches has been initiated due to complaints of difficult to open blister and tablet breaks while opening the blister .

Terminated Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-842-13 D-1305-2022
Class II · Moderate risk

Testosterone Gel 1%

Superpotent Drug: Out of specification assay result was obtained during stability testing.

Terminated Wrong potency / content Teva Pharmaceuticals USA Inc NDC 0591-3216-17 D-1289-2022

Recalls by year